1-week hypofractionated adjuvant whole-breast radiotherapy: towards a new standard?

Affiliations

¹ Department of Radiotherapy, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Université Paris-Sud, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
² Department of Radiotherapy, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Université Paris-Sud, 114, rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: sofia.rivera@gustaveroussy.fr.

Comment

Antonin Levy et al. Lancet. 2020.

. 2020 May 23;395(10237):1588-1589.

doi: 10.1016/S0140-6736(20)30978-8. Epub 2020 Apr 28.

¹ Department of Radiotherapy, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Université Paris-Sud, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
² Department of Radiotherapy, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Université Paris-Sud, 114, rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: sofia.rivera@gustaveroussy.fr.

No abstract available

Figures

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE, Goodman A, Harnett A, Hopwood P, Kirby AM, Kirwan CC, Morris C, Nabi Z, Sawyer E, Somaiah N, Stones L, Syndikus I, Bliss JM, Yarnold JR; FAST-Forward Trial Management Group. Murray Brunt A, et al. Lancet. 2020 May 23;395(10237):1613-1626. doi: 10.1016/S0140-6736(20)30932-6. Epub 2020 Apr 28. Lancet. 2020. PMID: 32580883 Free PMC article. Clinical Trial.

1. Whelan TJ, Pignol JP, Levine MN. Long-term results of hypofractionated radiotherapy for breast cancer. N Engl J Med. 2010;362:513–520. - PubMed
1. Haviland JS, Owen JR, Dewar JA. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–1094. - PubMed
1. Murray Brunt A, Haviland JS, Wheatley DA. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)30932-6. published online April 28. - DOI - PMC - PubMed
1. Mamounas EP, Bandos H, Lembersky BC. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:88–99. - PMC - PubMed
1. Darby SC, Ewertz M, McGale P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998. - PubMed